Mycobacterium abscessus infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mycobacterium abscessus infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-clofazimine-and-drug-combination-for-treating-mycobacterium-abscessus-lung-disease-in-adult-patients/ Wed, 29 Apr 2026 14:23:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-clofazimine-and-drug-combination-for-treating-mycobacterium-abscessus-lung-disease-in-adult-patients/ This clinical trial is focused on finding the best treatment for a lung disease caused by an infection with Mycobacterium abscessus. This is a type of bacteria that can cause serious lung problems. The study will test several antibiotics to see which combination works best to clear the infection and is well-tolerated by patients. The antibiotics being studied include clofazimine, tigecycline, clarithromycin, azithromycin, imipenem, doxycycline, cilastatin, amikacin, rifabutin, cefoxitin, linezolid, moxifloxacin, ethambutol, sulfamethoxazole, and trimethoprim. Some of these medications are given by mouth, while others are given through an injection or infusion.

The purpose of the study is to determine which treatment regimen is most effective in clearing the Mycobacterium abscessus infection from the lungs while being safe and tolerable for patients. Participants in the study will receive one or more of these antibiotics, and their progress will be monitored over a period of time. The study will look for negative cultures, which means no bacteria are found in the sputum samples, as a sign of successful treatment. The study will also assess how well patients tolerate the medications, with a focus on minimizing any side effects.

Participants will be involved in the study for different lengths of time, depending on the treatment they receive. Some treatments may last up to 58 weeks, while others may be shorter. The study aims to ensure that the treatments are both effective and safe, with the goal of improving the health and quality of life for people with this challenging lung infection.

]]>